Use Of Myo-inositol Research Articles

Use of myo-inositol and other nutritional supplements for the primary prevention of gestational diabetes mellitus

Use of myo-inositol and other nutritional supplements for the primary prevention of gestational diabetes mellitus

Myo-inositol as a carbon source in Chlorella sp. production

The study aimed to investigate the possible use of myo-inositol as a carbon source in Chlorella sp. culture. Firstly, experiments were conducted with different myo-inositol concentrations and glycerol in flasks. Secondly, a laboratory-scale tubular photobioreactor (PBR) was operated with CO2 and myo-inositol to determine performance under industrial production conditions. The highest dry weight of the experiments with flasks was 1.62 ± 0.02 g.L−1 and was obtained with 1 g.L−1 myo-inositol concentration. Myo-inositol yielded two times higher lipid accumulation compared to glycerol in the experiment with flasks and 12 % compared to CO2 in the PBR experiment. The results revealed that myo-inositol is one of the most efficient carbon sources with 0.86 CBCR (carbon to biomass conversion rate). Even if myo-inositol is more expensive than many carbon sources such as CO2, high efficiency and less light energy expenses make it a competitive carbon source in Chlorella sp. production.

Mandibular Endochondral Growth Is Specifically Augmented by Nutritional Supplementation with Myo-Inositol Even in Rabbits.

Mandibular retrognathism occurs by insufficient mandibular growth and causes several issues, such as respiratory difficulty and diminished masticatory function. At present, functional orthodontic appliances are used for stimulating mandibular growth in pediatric cases. However, the effectiveness of functional appliances is not always stable in daily practices. A more effective, reliable, and safer therapeutic method for mandibular growth promotion would be helpful for growing mandibular retrognathism patients. As we previously discovered that nutritional supplementation of myo-inositol in growing mice specifically increases mandibular endochondral growth, we performed preclinical animal experiments in rabbits in this study. Briefly, six-week-old male Japanese white rabbits were fed with or without myo-inositol supplementation in laboratory chow until 25 weeks old, and 3D image analysis using micro CT data and histological examinations was done. Myo-inositol had no systemic effect, such as femur length, though myo-inositol specifically augmented the mandibular growth. Myo-inositol increased the thickness of mandibular condylar cartilage. We discovered that the nutritional supplementation of myo-inositol during the growth period specifically augmented mandibular growth without any systemic influence, even in rabbits. Our results suggest the possibility of clinical use of myo-inositol for augmentation of the mandibular growth in growing mandibular retrognathism patients in the future.

Myoinositol or D-chiro-inositol for PCOS symptoms in adolescents: a narrative review.

Polycystic ovary syndrome (PCOS) treatment in adolescents currently focuses on lifestyle interventions, with pharmacological treatment options often limited to hormonal contraceptives. Several of these carry broad side-effect profiles and are not always accepted by young girls. There is growing interest in non-hormonal therapies for PCOS. We aimed to collate the evidence on the use of myoinositol or D-chiro-inositol in the improvement of PCOS symptoms in symptomatic adolescents. A systematic literature review identifying key articles from inception to March 2023. Participants: Female adolescents (aged 12-19 years) with PCOS or PCOS-like features. Intervention: Myoinositol or D-chiro-inositol with or without additional interventions. Comparison: Any other treatment, including lifestyle interventions, hormonal therapy, metformin or no treatment. The main outcome measure were improvement in symptoms, quality of life and adverse effects. Eight studies were included: two randomised open-label trials, one quasi-randomised and three non-randomised interventional studies, one case-control study and one cohort study. All studies showed improvements in some biochemical markers, metabolic parameters or clinical symptoms, but these were not reproducible across all studies. The benefit of myoinositol in adolescents with PCOS remains unclear, with limited high-quality evidence. This review highlights the need for robustly conducted research to inform clinical practice.

The effect of the combined use of myo-inositol, vitaminD and selenium on the cytokine status in women of reproductive age with autoimmune thyroiditis

Background. In recent years, in Ukraine and other countries of the world, there has been an increase in the frequency of autoimmune thyropathies. A significant role in the pathogenesis of autoimmune thyroiditis (AIT) is played by cytokines whose production is increased significantly during immunopathological reactions. The purpose of study was to investigate the effect of the combined use of myo-inositol, vitamin D and selenium on the cytokine status of women with euthyroidism, subclinical hypothyroidism and overt hypothyroidism against the background of autoimmune thyroiditis. Materials and methods. One hundred and forty-seven women aged 18–43 with AIT and 30women of the control group were under observation. Patients of first group (n = 74) received myo-inositol at a dose of 2000 mg/day, cholecalciferol 2000 IU/day, and selenium 100 μg/day additionally to the main treatment. Patients of the second group (n = 73) received only cholecalciferol at a dose of 2000 IU/day and selenium 100μg/day additionally to the main treatment. The functional state of the thyroid gland was studied by determining the levels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine, antibodies to thyroid peroxidase (Ab-TPO) and antibodies to thyroglobulin (Ab-TG). The state of the systemic and local inflammatory process was evaluated according to parameters of tumor necrosis factor α, interleukins 6, 10, 17, and 23. Results. It should be noted all patients with AIT had changes in cytokine status, with some differences depending on the clinical variant of autoimmune thyroid disease. After three months of treatment of patients of the first group with myo-inositol at a dose of 2000 mg/day, cholecalciferol 2000 IU/day and selenium 100 μg/day, and patients of the second group only with cholecalciferol at a dose of 2000 IU/day and selenium at 100 μg /day, a significant difference was found between the indicators in both studied cohorts. Conclusions. The administration of myo-inositol, vitamin D, and selenium had a combination effect on the reduction of cytokine indicators, Ab-TPO and Ab-TG levels, which contributed to the compensation of the underlying disease.

A Comparative Study of Myoinositol and Metformin for Ovulation Induction in Pregnant Women with PCOS

Introduction: PCOS is a common condition in women of reproductive age characterized by ovulatory dysfunction, androgen excess and polycystic ovaries. Myoinositol and metformin have both been studied as potential treatment options for inducing ovulation in women with PCOS. Aim of the Study: The aim of the study was to compare the use of myoinositol and metformin for ovulation induction in pregnant women with PCOS. Methods: This comparative observational cross-sectional study was conducted at the Manikganj 250 Bedded Sadar hospital, Dhaka, Bangladesh from January 2022 to December 2022. A total of 100 patients with PCOS were selected for this study. The participants were divided into 2 equal groups of 50 patients each, where patients in the first group were treated with myoinositol, and patients in the second group were treated with metformin. Result: In our study, there was a decrease in mean weight, BMI, and waist-hip ratio of both groups after treatment but with no statistically significant (p>0.05) difference between the groups. There was an improvement in menstrual cycle in both groups after treatment with no statistically significant (p>0.05) difference between the groups. The LH/FSH ratio decreased more in the myoinositol group after treatment compared to the metformin group but there was no statistically significant (p>0.05) difference between the groups. Fasting Insulin decreased similarly in both groups but there was no statistically significant (p>0.05) difference between the groups. HOMA-IR decreased in both groups with a statistically significant (p<0.05) difference after treatment. We found that myo-inositol administration in PCOS subjects led to statistically significant (p<0.05) decreases in FAI compared to the metformin group. Ovarian volume decreased from 12.59±5.15 cm3 to 10.05±4.50 cm3 in the myoinositol group and 12.90±5.62 cm3 to 10.65±4.10 cm3 in metformin group. The groups had no statistically significant (p>0.05) difference. The conception ....

Use of myo-inositol in women with polycystic ovary syndrome in the application of auxiliary reproductive technologies

Introduction. A large number of treatments for women with PCOS are currently under consideration. Treatment with myo-inositol is one of the new approaches to the treatment of PCOS. Aim. To study the effect of myo-inositol on the restoration of reproductive function in women with polycystic ovary syndrome using assisted reproductive technologies. Materials and methods. We conducted a systematic search and analysis of scientific papers in PubMed, MEDLINE, Embase, eLIBRARY, CyberLeninka and Google Scholar using the search PCOS, myo-inositol therapy and assisted reproductive technologies in PCOS terms. Results and discussion. In the development of PCOS, insulin resistance and hyperandrogenism play a role in 30–40 % of cases. Myo-inositol, which is an endogenous metabolite of the human body, is involved in the synthesis of inositol phosphate derivatives, which are necessary for signal transmission from insulin, GnRH, LH, FSH receptors. This substance helps to increase insulin sensitivity, which can reduce hyperandrogenism and improve the menstrual cycle. We analyzed the literature on the use of MI in women with PCOS with assisted reproductive technologies, since Myo-inositol is effective in normalizing ovarian function, improving the quality of oocytes and embryos in PCOS. Conclusion. The studies we examined show improvements in ovarian function, oocyte and embryo quality in patients taking myo-inositol combined with other drugs. However, further examination of large multicenter, randomized, controlled studies are needed to evaluate pregnancy and live births, as there are sources that do not confirm the efficacy of myo-inositol therapy.

Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a Prospective Case-Control Analysis.

The progressive improvement of lymphoma treatment has led to an important prolongation of patient survival and life expectancy. The principal international scientific societies of oncology now therefore recommend that long-term survivors of lymphoma join fertility programs. Specifically, fertile-age patients should be assisted by a multidisciplinary team, including specialists dedicated to fertility preservation in oncology, in order to support the completion of their reproductive project. In the general population, the use of Myo-Inositol and D-Chiro-Inositol (MI/DCI) has been demonstrated to be an effective choice to treat ovarian dysfunctions, with a consequent improvement in reproductive outcomes, so it may represent an adjuvant strategy for this purpose. We therefore conducted a pilot prospective case–control study to evaluate the potentialities of this nutritional supplement, with the aim of optimizing reproductive function in female long-term survivors of lymphoma. One group underwent oral supplementation with MI 1200 mg and DCI 135 mg per day for 12 months, compared with controls who underwent no treatment in the same period. After 12 months, FSH, LH, and progesterone levels, as well as oligomenorrhea and antral follicle count (AFC), were significantly improved in the MI/DCI group. In addition, a significantly higher mean value in FSH and LH and a significantly lower mean AFC value in the right ovary were observed in controls compared to the MI/DCI group. Despite the need for further investigation, MI/DCI could be considered a potential adjuvant strategy to restore ovarian function in female long-term survivors of lymphoma.

Myo-inositol in polycystic ovary syndrome: a systematic review and positioning of its use

Introduction: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disease among women of reproductive age 6 to 15% its presentation is complex and heterogeneous and is characterized by clinical and laboratory findings of hyperandrogenism, oligo-anovulation, metabolic abnormalities such as insulin resistance (IR), overweight, obesity, type 2 diabetes mellitus, dyslipidemia and increased risk of cardiovascular disease. Objective: To evaluate the effects of myo-inositol in pregnant and non-pregnant women with polycystic ovary syndrome in relation to fertility improvement, gestational outcomes, and metabolic and hormonal parameters. Methods: Data from randomized clinical trials on the efficacy of myo-inositol in women with PCOS were used in this review. The PubMed database was used for literature search. Results: Insulin resistance is one of the mechanisms that explain the emergence of metabolic and reproductive changes in women with PCOS. When compared to placebo, myo-inositol was effective in improving fertility, increasing ovulation and fertilization rates, in addition to improving metabolic parameters as indicators of insulin resistance (HOMA index). Even when compared to more traditional insulin sensitizers like metformin, myoinositol showed similar efficacy in restoring fertility. Myo-inositol was also effective when associated with clomiphene acetate and in women undergoing in vitro fertilization processes. There was also an improvement in pregnancy outcomes and a reduction in the risk of developing gestational diabetes with the use of myo-inositol. Conclusions: Myo-inositol improves clinical and laboratory parameters in both pregnant and non-pregnant PCOS patients, increasing the fertility rate and improving pregnancy outcomes.

Metabolic engineering of Corynebacterium glutamicum for production of scyllo-inositol, a drug candidate against Alzheimer's disease

Scyllo-inositol has been identified as a potential drug for the treatment of Alzheimer's disease. Therefore, cost-efficient processes for the production of this compound are desirable. In this study, we analyzed and engineered Corynebacterium glutamicum with the aim to develop competitive scyllo-inositol producer strains. Initial studies revealed that C. glutamicum naturally produces scyllo-inositol when cultured with myo-inositol as carbon source. The conversion involves NAD+-dependent oxidation of myo-inositol to 2-keto-myo-inositol followed by NADPH-dependent reduction to scyllo-inositol. Use of myo-inositol for biomass formation was prevented by deletion of a cluster of 16 genes involved in myo-inositol catabolism (strain MB001(DE3)Δiol1). Deletion of a second cluster of four genes (oxiC-cg3390-oxiD-oxiE) related to inositol metabolism prevented conversion of 2-keto-myo-inositol to undesired products causing brown coloration (strain MB001(DE3)Δiol1Δiol2). The two chassis strains were used for plasmid-based overproduction of myo-inositol dehydrogenase (IolG) and scyllo-inositol dehydrogenase (IolW). In BHI medium containing glucose and myo-inositol, a complete conversion of the consumed myo-inositol into scyllo-inositol was achieved with the Δiol1Δiol2 strain. To enable scyllo-inositol production from cheap carbon sources, myo-inositol 1-phosphate synthase (Ino1) and myo-inositol 1-phosphatase (ImpA), which convert glucose 6-phosphate into myo-inositol, were overproduced in addition to IolG and IolW using plasmid pSI. Strain MB001(DE3)Δiol1Δiol2 (pSI) produced 1.8 g/L scyllo-inositol from 20 g/L glucose and even 4.4 g/L scyllo-inositol from 20 g/L sucrose within 72 h. Our results demonstrate that C. glutamicum is an attractive host for the biotechnological production of scyllo-inositol and potentially further myo-inositol-derived products.

Respiratory Mitochondrial Efficiency and DNA Oxidation in Human Sperm after In Vitro Myo-Inositol Treatment.

Semen samples are known to contain abnormal amounts of reactive oxygen species (ROS) and oxygen free radicals; therefore, the identification of antioxidant molecules able to counteract the oxidative damage caused by ROS is foresight. Indeed, improving semen quality in terms of motility and reduction in DNA damage, can significantly improve the fertilization potential of sperm in vitro. To this regard, myo-inositol, based on its antioxidant properties, has been reported to be effective in improving sperm quality and motility in oligoasthenozoospermic patients undergoing assisted reproduction techniques when used as a dietary supplementation. Moreover, in vitro treatment demonstrated a direct relationship between myo-inositol, mitochondrial membrane potential and sperm motility. This experimental study aimed to evaluate the effects of myo-inositol (Andrositol-lab) in vitro treatment on sperm motility, capacitation, mitochondrial oxidative phosphorylation and DNA damage. Our results demonstrate that myo-inositol induces a significant increase in sperm motility and in oxygen consumption, the main index of oxidative phosphorylation efficiency and ATP production, both in basal and in in vitro capacitated samples. Moreover, we provide evidence for a significant protective role of myo-inositol against oxidative damage to DNA, thus supporting the in vitro use of myo-inositol in assisted reproductive techniques. Even if further studies are needed to clarify the mechanisms underlying the antioxidant properties of myo-inositol, the present findings significantly extend our knowledge on human male fertility and pave the way to the definition of evidence-based guidelines, aiming to improve the in vitro procedure currently used in ART laboratory for sperm selection.

The effect of Myo-inositol on sperm parameters and pregnancy rate in oligoasthenospermic men treated with IUI: A randomized clinical trial.

BackgroundIn about 40% of the couples, the cause of infertility problems is attributed to men because of low sperm production and disturbed motility of sperm. Pieces of evidence show that Myo-inositol has a potential role for the treatment of sperm morphology and male fertility.ObjectiveThis study aimed to determine the effect of Myo-inositol on the sperm parameters and fertility rate in patients with oligoasthenospermia treated by intrauterine insemination (IUI).Materials and MethodsThis study was a randomized clinical trial conducted on 37 patients with oligoasthenospermia treated by IUI during 2016-2017. In this study, the patients were randomly divided into two groups of oligoasthenospermia treated with (Case group) and without Myo-inositol (Control group). The case group received 0.5 ml of Myo-inositol with a concentration of 2 mg/ml and incubated at 37°C incubator for 2 hr, but the control group had no interventions.ResultsThe results of this study showed that although there was no significant difference in sperm parameters including sperm motility and concentration before processing with Myo-inositol in the case group, but there was a significant increase in sperm motility during the treatment with Myo-inositol. The therapeutic effect of this method was confirmed on induction of pregnancy in 18% of the treated patients, in such a way that was about twice greater than those who did not receive the drug.ConclusionAccording to the results of this study, the use of Myo-inositol is efficient enough to change sperm parameters to increase the chance of fertility.

Iodine and Myo-Inositol: A Novel Promising Combination for Iodine Deficiency.

Despite universal salt iodization programmes implemented over the last decades, iodine deficiency remains a major public health problem in many countries worldwide. Endeavors are still required to ensure sufficient iodine intake in the populations at risk in order to eliminate deficiency. Iodine is crucial for the synthesis of thyroid hormones triiodothyronine (T3) and thyroxine (T4), as well as for the thyroid health. When iodine levels are insufficient, T4 attests toward the lower limit of the physiological range, causing subtle fluctuations in the T3:T4 ratio. Monitoring these variations may be an accurate way to assess patient's iodine status. Recently, a number of published clinical studies documented a growing interest toward the use of myo-inositol in thyroid diseases. Myo-inositol, a carbocyclic polyol, regulates the generation of hydrogen peroxide (H2O2) in thyrocytes, crucial for iodine organification and thyroid hormone biosynthesis. Thus, combined supplementation of iodine and myo-inositol may promote higher iodine availability in thyrocytes improving thyroid functionality. This review presents novel strategies for the diagnosis and the management of iodine deficiency, focusing on the potential role of myo-inositol combined with iodine.

Corrosion Assessment of Myo-Inositol Sugar Alcohol as a Phase Change Material in Storage Systems Connected to Fresnel Solar Plants.

Thermal energy storage systems work in conjunction with solar technologies with the aim of increasing their dispatchability and competitiveness in the energy market. Among others, latent heat thermal energy storage systems have become an appealing research subject and many efforts have therefore been invested in selecting the best phase change material (PCM) to fit the final application. In this study, an extended corrosion characterization was performed for two PCM candidates, solar salt (40 wt.% KNO3/60 wt.% NaNO3) and myo-inositol (C6H12O6), to be applied in Fresnel solar plants. Corrosion rates were determined in aluminium, stainless steel (AISI 304), carbon steel (AISI 1090), and copper by gravimetric tests, gauging the weight loss after 2000 h of immersion at 250 °C. The corrosion products were characterized by scanning electron microscopy (SEM) and x-ray diffraction (XRD). The corrosion tests carried out with myo-inositol did not show accurate enough results to draw conclusions regarding corrosion on the metals. However, it was observed that this sugar alcohol strongly sticks to the metal specimens, making myo-inositol extremely difficult to manage as an energy storage material. Therefore, the present paper discourages the use of myo-inositol as a PCM beyond its corrosion rate.

Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants

Previous studies of myo-inositol in preterm infants with respiratory distress found reduced severity of retinopathy of prematurity (ROP) and less frequent ROP, death, and intraventricular hemorrhage. However, no large trials have tested its efficacy or safety. To test the adverse events and efficacy of myo-inositol to reduce type 1 ROP among infants younger than 28 weeks' gestational age. Randomized clinical trial included 638 infants younger than 28 weeks' gestational age enrolled from 18 neonatal intensive care centers throughout the United States from April 17, 2014, to September 4, 2015; final date of follow-up was February 12, 2016. The planned enrollment of 1760 participants would permit detection of an absolute reduction in death or type 1 ROP of 7% with 90% power. The trial was terminated early due to a statistically significantly higher mortality rate in the myo-inositol group. A 40-mg/kg dose of myo-inositol was given every 12 hours (initially intravenously, then enterally when feeding; n = 317) or placebo (n = 321) for up to 10 weeks. Type 1 ROP or death before determination of ROP outcome was designated as unfavorable. The designated favorable outcome was survival without type 1 ROP. Among 638 infants (mean, 26 weeks' gestational age; 50% male), 632 (99%) received the trial drug or placebo and 589 (92%) had a study outcome. Death or type 1 ROP occurred more often in the myo-inositol group vs the placebo group (29% vs 21%, respectively; adjusted risk difference, 7% [95% CI, 0%-13%]; adjusted relative risk, 1.41 [95% CI, 1.08-1.83], P = .01). All-cause death before 55 weeks' postmenstrual age occurred in 18% of the myo-inositol group and in 11% of the placebo group (adjusted risk difference, 6% [95% CI, 0%-11%]; adjusted relative risk, 1.66 [95% CI, 1.14-2.43], P = .007). The most common serious adverse events up to 7 days of receiving the ending dose were necrotizing enterocolitis (6% for myo-inositol vs 4% for placebo), poor perfusion or hypotension (7% vs 4%, respectively), intraventricular hemorrhage (10% vs 9%), systemic infection (16% vs 11%), and respiratory distress (15% vs 13%). Among premature infants younger than 28 weeks' gestational age, treatment with myo-inositol for up to 10 weeks did not reduce the risk of type 1 ROP or death vs placebo. These findings do not support the use of myo-inositol among premature infants; however, the early termination of the trial limits definitive conclusions.

Применение миоинозитола в лечении женского бесплодия в программах вспомогательных репродуктивных технологий у пациенток с высоким риском получения незрелых гамет

Применение миоинозитола в лечении женского бесплодия в программах вспомогательных репродуктивных технологий у пациенток с высоким риском получения незрелых гамет

Use of Myo-inositol for Ovulation Induction in Patients with Polycystic Ovary Syndrome

Use of Myo-inositol for Ovulation Induction in Patients with Polycystic Ovary Syndrome

Dietary supplementation with myo-inositol in women during pregnancy for treating gestational diabetes.

Dietary supplementation with myo-inositol in women during pregnancy for treating gestational diabetes.

Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.

Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.

Bioenergy and Biomass Utilization.

Bioenergy is of increasing interest as a renewable, environmentally friendly alternative to energy derived from fossil fuels. Through a variety of processes, biomass can be converted to solid, liquid, or gaseous biofuels. However, various challenges persist to the maintenance and development of biomass-to-energy utilization. This special issue focuses on the most recent advances in the frontier research of bioenergy and biomass utilization and features six selected papers with high quality. The paper titled “Nanofibrillated Cellulose and Copper Nanoparticles Embedded in Polyvinyl Alcohol Films for Antimicrobial Applications” by T. Zhong et al. develops a method to produce hybrids of TEMPO nanofibrillated cellulose (TNFC) and copper nanoparticles. The hybrid material is embedded in polyvinyl alcohol thermoplastic resin and the films are produced using a solvent casting method. The authors evaluate the films in terms of its morphology and thermal and antimicrobial properties and prove that TNFC-copper nanoparticles as antimicrobial nanofillers are valuable for PVA applications. The paper titled “Response of Arbuscular Mycorrhizal Fungi to Hydrologic Gradients in the Rhizosphere of Phragmites australis (Cav.) Trin ex. Steudel Growing in the Sun Island Wetland” by L. Wang et al. assesses the variations of hydrologic gradients in the relationships among AM fungi, reed, and rhizospheric microorganisms. The authors discover water content in soil and reed growth parameters are both positively associated with AM fungi colonization, but only the positive correlations between reed biomass parameters and the colonization could be expected, or both the host plant biomass and the AM fungi could be beneficial. This study could shed light on the mechanisms inside AM fungi-reed symbioses and would be referred to for optimizing the combined phytorhizoremediation. The paper titled “Production by Tobacco Transplastomic Plants of Recombinant Fungal and Bacterial Cell-Wall Degrading Enzymes to Be Used for Cellulosic Biomass Saccharification” by L. Paolo et al. presents work on saccharification of plant biomass. The authors express in tobacco chloroplasts microbial genes encoding five cellulases and a polygalacturonase. Leaf extracts containing the recombinant enzymes show the ability to degrade various cell-wall components under different conditions. In addition, a thermostable xylanase is also tested in combination with a cellulase and a polygalacturonase to study the cumulative effect on the depolymerization of a complex plant substrate. Results demonstrate the feasibility of using transplastomic tobacco leaf extracts to convert cell-wall polysaccharides into reducing sugars, fulfilling a major prerequisite of large scale availability of a variety of cell-wall degrading enzymes for biofuel industry. The paper titled “Enzymatic Saccharification of Lignocellulosic Residues by Cellulases Obtained from Solid State Fermentation Using Trichoderma viride” by T. Sartori et al. presents an approach that uses cellulolytic complex produced by Trichoderma viride in solid state fermentation to hydrolyze lignocellulosic residues. This produced enzyme shows viability in comparison with the commercial cellulase enzyme. The synthesis of cellulases by microorganisms from lignocellulosic residues is a process of great interest, representing the search for renewable sources to replace the fossil energetic matrix. The paper titled “Improving Biomethane Production and Mass Bioconversion of Corn Stover Anaerobic Digestion by Adding NaOH Pretreatment and Trace Elements” by C. Liu et al. describes an approach to improve biomethane production from corn stover. The authors use NaOH pretreatment and trace elements supplementation as a strategy to enhance the biodegradability of corn stover for biomethane production. The approach is compared with only NaOH-pretreated and untreated corn stover, and the paper highlights the supplementation of trace elements. The paper titled “Biochemical Modulation of Lipid Pathway in Microalgae Dunaliella sp. for Biodiesel Production,” by A. F. Talebi et al., explores the use of myoinositol to modulate LP and biodiesel quality. Inclusion of myoinositol in the media indeed improves the total lipid accumulation and biodiesel quality parameters, and this work highlights the fact that the biochemical modulation strategies should be progressively considered in the hope of finding more efficient and economically feasible strategies leading to more viable production systems.